[go: up one dir, main page]

AR097199A1 - Inhibidores de rorc2 y sus métodos de uso - Google Patents

Inhibidores de rorc2 y sus métodos de uso

Info

Publication number
AR097199A1
AR097199A1 ARP140102904A ARP140102904A AR097199A1 AR 097199 A1 AR097199 A1 AR 097199A1 AR P140102904 A ARP140102904 A AR P140102904A AR P140102904 A ARP140102904 A AR P140102904A AR 097199 A1 AR097199 A1 AR 097199A1
Authority
AR
Argentina
Prior art keywords
4alkyl
ch2c
group
6alkyl
independently selected
Prior art date
Application number
ARP140102904A
Other languages
English (en)
Inventor
Jay Meyers Marvin
Edward Schnute Mark
Thorarensen Atli
Robert Blinn James
Christopher Flick Andrew
Wennerstl Gran Mattias
Jones Peter
Kaila Neelu
Richard Kiefer James Jr
Richard Mente Scot
Zamaratski Edouard
Wolfgang Zapf Christoph
Xing Li
G Kurumbail Ravi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR097199A1 publication Critical patent/AR097199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos, composiciones farmacéuticas, métodos para inhibir la actividad de RORg y/o reducir la cantidad de IL-17 en un sujeto, y métodos para tratar los diversos trastornos médicos usando estos compuestos y composiciones farmacéuticas. Compuestos útiles para tratar trastornos inflamatorios e inmunitorios. Reivindicación 1: Un compuesto caracterizado por las fórmulas (1), (2), (3), (4), (5), (6) ó (7), o una sal aceptable desde el punto de vista farmacéutico, un metabolito farmacéuticamente activo, un profármaco aceptable desde el punto de vista farmacéutico o un solvato de aquel aceptable desde el punto de vista farmacéutico, en donde, Y es hidrógeno, halo, ciano, C₁₋₃alquilo, C₁₋₃hidroxialquilo, C₁₋₅alquenilo, C₁₋₃haloalquilo, C₁₋₃hidroxihaloalquilo, C₃₋₆cicloalquilo, C₁₋₃alcoxi o C₁₋₃haloalcoxi; R¹ es hidrógeno, C₁₋₆alquilo, C₁₋₆hidroxialquilo o C₁₋₆haloalquilo; X es un compuesto seleccionado del grupo de fórmulas (8); R² es C₁₋₆alquilo, C₃₋₈cicloalquilo, C₃₋₈heterocicloalquilo, arilo o heteroarilo, sustituido opcionalmente con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente, para cada caso, del grupo que consiste en halo, ciano, C₁₋₄alquilo, C₁₋₄haloalquilo, C₁₋₄cianoalquilo, hidroxilo, -OR, C₁₋₄hidroxialquilo, C₁₋₄hidroxialcoxi, C₁₋₄hidroxialcoxiC₁₋₄alquilo, C₁₋₄alcoxi, C₁₋₄alcoxiC₁₋₄alquilo, C₁₋₄alcoxiC₁₋₄alcoxi, C₁₋₄alcoxiC₁₋₄alcoxiC₁₋₄alquilo, C₁₋₄haloalcoxi, -NR₂, (R₂N)C₁₋₄alquil-, C₁₋₄alquiltio, C₁₋₄haloalquiltio, -C(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NR₂, -N(R)C(=O)R, -CH₂C(=O)R, -CH₂C(=O)OR, -CH₂OC(=O)R, -CH₂C(=O)NR₂, -CH₂N(R)C(=O)R, -S(=O)₂R, -S(=O)₂NR₂, -N(R)S(=O)₂R, -A y -CH₂A; R se selecciona independientemente, para cada caso, del grupo que consiste en hidrógeno, C₁₋₄alquilo, C₁₋₄haloalquilo, C₁₋₄cianoalquilo, C₁₋₄hidroxialquilo, C₃₋₈cicloalquilo o C₃₋₈heterocicloalquilo; o en donde un nitrógeno se sustituye con dos grupos R, que se pueden tomar juntos con el átomo de nitrógeno al cual están unidos para formar un C₃₋₈heterocicloalquilo saturado de 4, 5, 6 ó 7 miembros que, cuando se forma, se puede sustituir opcionalmente con 1, 2 ó 3 sustituyentes seleccionados independientemente del grupo que consiste en C₁₋₄alquilo, halo, hidroxilo, C₁₋₄hidroxialquilo, C₁₋₄cianoalquilo, C₁₋₄haloalquilo y =O; A se selecciona independientemente, para cada caso, del grupo que consiste en C₃₋₈cicloalquilo, C₃₋₈heterocicloalquilo, arilo y heteroarilo, sustituido opcionalmente con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente, para cada caso, del grupo que consiste en halo, ciano, C₁₋₄alquilo, C₁₋₄haloalquilo, C₁₋₄cianoalquilo, hidroxilo, C₁₋₄hidroxialquilo, C₁₋₄alcoxi, C₁₋₄alcoxiC₁₋₄alquilo, C₁₋₄haloalcoxi, -NR₂, (R₂N)C₁₋₄alquil-, C₁₋₄alquiltio, C₁₋₄haloalquiltio, -C(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NR₂, -N(R)C(=O)R, -CH₂C(=O)R, -CH₂C(=O)OR, -CH₂OC(=O)R, -CH₂C(=O)NR₂, -CH₂N(R)C(=O)R, -S(=O)₂R, -S(=O)₂NR₂ y -N(R)S(=O)₂R; W es un resto seleccionado del grupo de fórmulas (9), sustituido opcionalmente con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente, para cada caso, del grupo que consiste en halo, C₁₋₆alquilo, C₁₋₆hidroxialquilo y C₁₋₆haloalquilo; R³ es C₁₋₆alquilo, C₃₋₈cicloalquilo, C₃₋₈heterocicloalquilo, arilo, heteroarilo, -C(=O)R⁴, -C(=O)OR⁴, -C(=O)N(R⁵)₂ o -S(=O)₂R⁴, sustituido opcionalmente con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente, para cada caso, del grupo que consiste en halo, ciano, C₁₋₄alquilo, C₁₋₄haloalquilo, C₁₋₄cianoalquilo, hidroxilo, C₁₋₄hidroxialquilo, C₁₋₄alcoxi, C₁₋₄alcoxiC₁₋₄alquilo, C₁₋₄haloalcoxi, -NR₂, (R₂N)C₁₋₄alquil-, C₁₋₄alquiltio, C₁₋₄haloalquiltio, -C(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NR₂, -N(R)C(=O)R, -CH₂C(=O)R, -CH₂C(=O)OR, -CH₂OC(=O)R, -CH₂C(=O)NR₂, -CH₂N(R)C(=O)R, -S(=O)₂R, -S(=O)₂NR₂, -N(R)S(=O)₂R, -A y-CH₂A; R⁴ es hidrógeno, C₁₋₆alquilo, C₃₋₈cicloalquilo, C₃₋₈heterocicloalquilo, C₃₋₈cicloalquilC₁₋₆alquilo, C₃₋₈heterocicloalquilC₁₋₆alquilo, arilo o heteroarilo, sustituido opcionalmente con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente, para cada caso, del grupo que consiste en halo, ciano, C₁₋₄alquilo, C₁₋₄haloalquilo, C₁₋₄cianoalquilo, hidroxilo, C₁₋₄hidroxialquilo, C₁₋₄alcoxi, C₁₋₆alcoxiC₁₋₆alquilo, C₁₋₆haloalcoxi, -NR₂, (R₂N)C₁₋₆alquilo, C₁₋₆alquiltio, C₁₋₆haloalquiltio, -C(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NR₂, -N(R)C(=O)R, -CH₂C(=O)R, -CH₂C(=O)OR, -CH₂OC(=O)R, -CH₂C(=O)NR₂, -CH₂N(R)C(=O)R, -S(=O)₂R, -S(=O)₂NR₂, -N(R)S(=O)₂R, -A Y -CH₂A; y R⁵ se selecciona independientemente, para cada caso, del grupo que consiste en hidrógeno, C₁₋₆alquilo, C₃₋₈cicloalquilo, C₃₋₈heterocicloalquilo, C₃₋₈cicloalquilC₁₋₆alquilo, C₃₋₈heterocicloalquilC₁₋₆alquilo, arilo y heteroarilo, sustituido opcionalmente con 1, 2, 3, 4 ó 5 sustituyentes, seleccionados independientemente, para cada caso, del grupo que consiste en halo, ciano, C₁₋₄alquilo, C₁₋₄haloalquilo, C₁₋₄cianoalquilo, hidroxilo, C₁₋₄hidroxialquilo, C₁₋₄alcoxi, C₁₋₄alcoxiC₁₋₄alquilo, C₁₋₄haloalcoxi, -NR₂, (R₂N)C₁₋₄alquil-, C₁₋₄alquiltio, C₁₋₄haloalquiltio, -C(=O)R, -C(=O)OR, -OC(=O)R, -C(=O)NR₂, -N(R)C(=O)R, -CH₂C(=O)R, -CH₂C(=O)OR, -CH₂OC(=O)R, -CH₂C(=O)NR₂, -CH₂N(R)C(=O)R, -S(=O)₂R, -S(=O)₂NR₂, -N(R)S(=O)₂R, -A y -CH₂A; o en donde un nitrógeno se sustituye con dos grupos R⁵ que pueden tomarse junto el átomo de nitrógeno al que están unidos para formar un C₃₋₈ heterocicloalquilo saturado de 4, 5, 6 ó 7 miembros que, cuando se forma, se puede sustituir opcionalmente con 1, 2 ó 3 sustituyentes seleccionados independientemente del grupo que consiste en C₁₋₄alquilo, halo, hidroxilo, C₁₋₄hidroxialquilo, C₁₋₄haloalquilo y =O.
ARP140102904A 2013-08-02 2014-08-01 Inhibidores de rorc2 y sus métodos de uso AR097199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361861709P 2013-08-02 2013-08-02

Publications (1)

Publication Number Publication Date
AR097199A1 true AR097199A1 (es) 2016-02-24

Family

ID=51570793

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102904A AR097199A1 (es) 2013-08-02 2014-08-01 Inhibidores de rorc2 y sus métodos de uso

Country Status (41)

Country Link
US (6) US20160046597A1 (es)
EP (2) EP3027603B1 (es)
JP (1) JP6224832B2 (es)
KR (1) KR101821903B1 (es)
CN (1) CN105492434B (es)
AP (1) AP2016009017A0 (es)
AR (1) AR097199A1 (es)
AU (1) AU2014298017B2 (es)
BR (1) BR112016001781A2 (es)
CA (1) CA2919783C (es)
CL (1) CL2016000235A1 (es)
CR (1) CR20160047A (es)
CU (2) CU24398B1 (es)
CY (1) CY1120751T1 (es)
DK (1) DK3027603T3 (es)
DO (1) DOP2016000039A (es)
EA (1) EA029499B9 (es)
EC (1) ECSP16008797A (es)
ES (1) ES2685839T3 (es)
GE (2) GEP20186876B (es)
GT (1) GT201600027A (es)
HR (1) HRP20181291T1 (es)
HU (1) HUE039972T2 (es)
IL (1) IL243728B (es)
LT (1) LT3027603T (es)
MA (1) MA38810B1 (es)
MD (1) MD20160007A2 (es)
MX (1) MX2016001446A (es)
NI (1) NI201600021A (es)
PE (1) PE20160801A1 (es)
PH (1) PH12016500140A1 (es)
PL (1) PL3027603T3 (es)
PT (1) PT3027603T (es)
RS (1) RS57618B1 (es)
SG (1) SG11201600200QA (es)
SI (1) SI3027603T1 (es)
TN (1) TN2016000040A1 (es)
TW (2) TWI652263B (es)
UA (1) UA115908C2 (es)
UY (1) UY35687A (es)
WO (1) WO2015015378A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
CA2975157C (en) 2015-01-30 2019-09-17 Pfizer Inc. Sulfonamide-substituted indole modulators of rorc2 and methods of use thereof
US10336748B2 (en) * 2015-01-30 2019-07-02 Pfizer Inc. Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
CN104672121B (zh) * 2015-02-16 2017-10-24 上海华默西医药科技有限公司 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法
HRP20200064T1 (hr) * 2015-06-09 2020-04-03 Abbvie Inc. Modulatori nuklearnih receptora (ror) namijenjeni liječenju upalnih i autoimunih bolesti
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
CN109206401B (zh) * 2017-06-29 2021-03-05 南京柯菲平盛辉制药有限公司 一类甲基-1H-吲唑类RORγ调节剂及其用途
JP6557436B1 (ja) * 2018-03-12 2019-08-07 アッヴィ・インコーポレイテッド チロシンキナーゼ２媒介性シグナル伝達の阻害剤
WO2021007477A1 (en) 2019-07-11 2021-01-14 E-Scape Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
WO2021209377A1 (en) * 2020-04-16 2021-10-21 Basf Se A process for the preparation of 4-cyanobenzoyl chlorides
CN119119032B (zh) * 2024-08-05 2025-09-09 中山大学附属第三医院 一种吲哚苯甲酰胺类衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
WO1999007700A1 (en) * 1997-08-09 1999-02-18 Smithkline Beecham Plc Bicyclic compounds as ligands for 5-ht1 receptors
WO1999064044A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
CN102015707A (zh) * 2008-02-29 2011-04-13 阵列生物制药公司 Raf抑制剂化合物及其使用方法
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
EP2511263A1 (en) * 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2013064231A1 (en) * 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
JP6225178B2 (ja) * 2012-05-31 2017-11-01 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2013171729A2 (en) * 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator

Also Published As

Publication number Publication date
AU2014298017B2 (en) 2018-03-29
SG11201600200QA (en) 2016-02-26
CN105492434B (zh) 2018-02-16
CU20160015A7 (es) 2016-09-30
GEP20186876B (en) 2018-07-10
PH12016500140B1 (en) 2016-04-18
TN2016000040A1 (fr) 2017-07-05
AU2014298017A1 (en) 2016-02-11
US20160046597A1 (en) 2016-02-18
EA029499B9 (ru) 2018-07-31
US20170233371A1 (en) 2017-08-17
LT3027603T (lt) 2018-08-10
KR101821903B1 (ko) 2018-01-24
DK3027603T3 (en) 2018-09-17
TW201733998A (zh) 2017-10-01
US20180282304A1 (en) 2018-10-04
EP3027603B1 (en) 2018-07-18
ECSP16008797A (es) 2017-08-31
MA38810B1 (fr) 2018-06-29
CU24366B1 (es) 2018-10-04
CN105492434A (zh) 2016-04-13
DOP2016000039A (es) 2016-06-15
PE20160801A1 (es) 2016-08-24
ES2685839T3 (es) 2018-10-11
PH12016500140A1 (en) 2016-04-18
US20200039960A1 (en) 2020-02-06
GT201600027A (es) 2019-09-20
AP2016009017A0 (en) 2016-01-31
WO2015015378A3 (en) 2015-05-14
CA2919783A1 (en) 2015-02-05
SI3027603T1 (sl) 2018-10-30
NI201600021A (es) 2016-03-16
EA201690039A1 (ru) 2016-08-31
BR112016001781A2 (pt) 2017-08-01
HUE039972T2 (hu) 2019-02-28
WO2015015378A2 (en) 2015-02-05
US20180086736A1 (en) 2018-03-29
UA115908C2 (uk) 2018-01-10
CU20160145A7 (es) 2017-02-02
JP6224832B2 (ja) 2017-11-01
RS57618B1 (sr) 2018-11-30
MA38810A1 (fr) 2017-10-31
CY1120751T1 (el) 2019-12-11
TWI652263B (zh) 2019-03-01
HRP20181291T1 (hr) 2018-10-19
CU24398B1 (es) 2019-04-04
MX2016001446A (es) 2016-05-05
EP3027603A2 (en) 2016-06-08
IL243728A0 (en) 2016-04-21
PT3027603T (pt) 2018-10-11
PL3027603T3 (pl) 2019-03-29
EP3428160A1 (en) 2019-01-16
GEAP201814046A (en) 2018-03-12
UY35687A (es) 2015-02-27
CL2016000235A1 (es) 2017-07-07
JP2016528226A (ja) 2016-09-15
CA2919783C (en) 2018-02-06
MD20160007A2 (ro) 2016-06-30
IL243728B (en) 2018-10-31
HK1219093A1 (zh) 2017-03-24
KR20160037996A (ko) 2016-04-06
US20190144429A1 (en) 2019-05-16
TW201516041A (zh) 2015-05-01
CR20160047A (es) 2016-03-03
EA029499B1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
AR121016A2 (es) Sales de fenotiazindiaminio y su uso
AR090121A1 (es) Compuestos de oxazolidin-2-ona y usos de los mismos
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CU20160097A7 (es) Compuestos de imidazopirazina como inhibidores de syk
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR090589A1 (es) INHIBIDORES DE b-LACTAMASA ISOXAZOL
AR090590A1 (es) COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA
EA201690094A1 (ru) Ингибиторы syk
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR107032A1 (es) Inhibidores bicíclicos de pad4
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure